Journal of Pediatrics Review

Published by: Kowsar
Corrected Proof scheduled for 6 (2)

Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

Mohammad Sobhani Shahmirzadi 1 and Leila Barati 1 , *
Authors Information
1 Neonatal and Children’s Health Research Center, Taleghani Children’s Center, Golestan University of Medical Sciences, Gorgan, IR Iran
Article information
  • Journal of Pediatrics Review: , In Press (In Press); e11635
  • Published Online: October 8, 2017
  • Article Type: Review Article
  • Received: May 16, 2017
  • Revised: August 12, 2017
  • Accepted: August 23, 2017
  • DOI: 10.5812/jpr.11635

To Cite: Sobhani Shahmirzadi M, Barati L. Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review, J Pediatr Rev. Online ahead of Print ;In Press(In Press):e11635. doi: 10.5812/jpr.11635.

Abstract
Copyright: Copyright © 2017, Journal of Pediatrics Review. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Data Sources
3. Study Selection
4. Data Extraction
5. Results
6. Discussion
7. Conclusions
References
  • 1. Cho T, Kim YJ, Paik SS. The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2012; 15(4): 256-65[DOI][PubMed]
  • 2. Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012; 54(5): 700-13[DOI][PubMed]
  • 3. Ghergherehchi R, Hazhir N, Mostafa Gharehbaghi M. Lifestyle Intervention and Vitamin E Therapy in Obese Children with Nonalcoholic Fatty Liver Disease. J Comprehens Pediatr. 2012; 4(1): 62-5[DOI]
  • 4. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017; 64(2): 319-34[DOI][PubMed]
  • 5. Boyraz M, Pirgon O, Dundar B, Cekmez F, Hatipoglu N. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol. 2015; 7(2): 121-7[DOI][PubMed]
  • 6. Ode KL, Frohnert BI, Nathan BM. Identification and treatment of metabolic complications in pediatric obesity. Rev Endocr Metab Disord. 2009; 10(3): 167-88[DOI][PubMed]
  • 7. Della Corte C, Carpino G, De Vito R, De Stefanis C, Alisi A, Cianfarani S, et al. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS One. 2016; 11(12)[DOI][PubMed]
  • 8. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005; 33(2): 68-71[DOI][PubMed]
  • 9. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009; 58(11): 1538-44[DOI][PubMed]
  • 10. Ramon-Krauel M, Salsberg SL, Ebbeling CB, Voss SD, Mulkern RV, Apura MM, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013; 9(3): 252-60[DOI][PubMed]
  • 11. Koot BG, van der Baan-Slootweg OH, Vinke S, Bohte AE, Tamminga-Smeulders CL, Jansen PL, et al. Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int J Obes (Lond). 2016; 40(1): 51-7[DOI][PubMed]
  • 12. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008; 48(1): 119-28[DOI][PubMed]
  • 13. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr. 1994; 125(2): 239-41[PubMed]
  • 14. Espghan Committee on Nutrition , Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, et al. Role of dietary factors and food habits in the development of childhood obesity: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2011; 52(6): 662-9[DOI][PubMed]
  • 15. St-Jules DE, Watters CA, Brunt EM, Wilkens LR, Novotny R, Belt P, et al. Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2013; 57(5): 627-33[DOI][PubMed]
  • 16. Chen LH, Wang YF, Xu QH, Chen SS. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2016; [DOI][PubMed]
  • 17. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012; 56(4): 944-51[DOI][PubMed]
  • 18. Nobili V, Alisi A, Della Corte C, Rise P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013; 23(11): 1066-70[DOI][PubMed]
  • 19. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011; 96(4): 350-3[DOI][PubMed]
  • 20. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16): 1659-68[DOI][PubMed]
  • 21. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000; 136(6): 734-8[PubMed]
  • 22. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005; 21(7): 871-9[DOI][PubMed]
  • 23. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther. 2008; 30(6): 1168-76[DOI][PubMed]
  • 24. Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 2010; 31(1): 62-70[DOI][PubMed]
  • 25. Hourigan SK, Abrams S, Yates K, Pfeifer K, Torbenson M, Murray K, et al. Relation between vitamin D status and nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr. 2015; 60(3): 396-404[DOI][PubMed]
  • 26. Vajro P, Mandato C, Veropalumbo C, De Micco I. Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease. Ann Hepatol. 2013; 12(1): 161-3[PubMed]
  • 27. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014; 39(11): 1276-85[DOI][PubMed]
  • 28. Nadler EP, Reddy S, Isenalumhe A, Youn HA, Peck V, Ren CJ, et al. Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. J Am Coll Surg. 2009; 209(5): 638-44[DOI][PubMed]
  • 29. Perito ER, Rodriguez LA, Lustig RH. Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2013; 29(2): 170-6[DOI][PubMed]
  • 30. Calder PC. Very long chain omega‐3 (n‐3) fatty acids and human health. Eur J Lipid Sci Technol. 2014; 116(10): 1280-300
  • 31. Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. J Pediatr. 2015; 166(6): 1358-63 e1-3[DOI][PubMed]
  • 32. Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014; 9(2)[DOI][PubMed]
  • 33. Vajro P, Veropalumbo C, D'Aniello R, Mandato C. Probiotics in the treatment of non alcoholic fatty liver disease: further evidence in obese children. Nutr Metab Cardiovasc Dis. 2013; 23(1)
  • 34. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011; 52(6): 740-3[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader